Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. Curative treatment for patients with ...
Bevacizumab plus chemotherapy as first-line therapy for elderly patients with metastatic colorectal cancer: Interim results of the noninterventional CASSIOPEE study.
Family physicians' colonoscopy rates decreased from 11.32% in 2016 to 6.73% in 2021, influenced by patient demographics and financial factors. TAS-102 plus bevacizumab is cost-effective in China but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback